24-去甲熊去氧胆酸通过靶向TH17致病性与转分化改善肠道炎症
本研究在多种小鼠模型中探索24-去甲熊去氧胆酸(NorUDCA)对TH17细胞的免疫调节作用。NorUDCA抑制TH17效应功能、减少促炎性「TH1样-TH17」细胞生成,并促进TH17向Treg和Tr1细胞转分化,机制涉及减弱谷氨酰胺-mTORC1-糖酵解信号轴,并在人源化NSG小鼠模型中得到验证。
要点
- NorUDCA抑制TH17效应功能并增加Treg数量。
- NorUDCA减少促炎性「TH1样-TH17」细胞并促进TH17向Treg和Tr1转分化。
- NorUDCA通过减弱谷氨酰胺-mTORC1-糖酵解信号轴发挥作用。
核心结论
- NorUDCA在多种小鼠模型中限制TH17炎症,有望用于治疗TH17介导的肠道疾病及其他疾病。
研究设计与样本
- 采用CD4+初始T细胞过继转移小鼠模型评估NorUDCA对TH17分化的影响。
- 采用αCD3刺激模型联合白细胞介素-17A命运图谱评估对上皮内TH17致病性和转分化的影响。
- 机制研究使用分子和多组学方法、流式细胞术及代谢测定,对象为致病性TH17细胞。
- 在过继转移至肠道组织或中枢神经系统后评估体外暴露于NorUDCA的致病性TH17细胞的致病性。
- 在人源化NSG小鼠模型(重建PSC患者外周血单个核细胞并接受αCD3刺激)中验证关键发现。
主要发现
- NorUDCA在CD4+初始T细胞过继转移后抑制TH17效应功能并富集调节性T细胞(Treg)。
- NorUDCA在αCD3模型中减轻上皮内TH17致病性、减少促炎性「TH1样-TH17」细胞生成,并增强TH17向Treg和Tr1细胞转分化。
- 体内消除实验显示Treg诱导对NorUDCA抗TH17致病性炎症效应至关重要。
- 机制上,NorUDCA通过减弱谷氨酰胺-mTORC1-糖酵解信号轴,在体外抑制致病性TH17效应功能并促进功能性Treg形成。
- 体外暴露于NorUDCA的致病性TH17细胞在转移至肠道或中枢神经系统后致病性和扩增减弱,且NorUDCA对TH17炎症的影响在人源化NSG小鼠模型中得到证实。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: 24-Nor-ursodeoxycholic acid (NorUDCA) is a novel therapeutic bile acid for treating immune-mediated cholestatic liver diseases, such as primary sclerosing cholangitis (PSC). OBJECTIVE: Since PSC strongly associates with T helper-type-like 17 (TH17)-mediated intestinal inflammation, we explored NorUDCA's immunomodulatory potential on TH17 cells. DESIGN: NorUDCA's impact on TH17 differentiation was assessed using a CD4+TNaive adoptive transfer mouse model, and on intraepithelial TH17 pathogenicity and transdifferentiation using an αCD3 stimulation model combined with interleukin-17A-fate-mapping. Mechanistic studies used molecular and multiomics approaches, flow cytometry and metabolic assays with pathogenic (p) TH17. Pathogenicity of pTH17 exposed to NorUDCA in vitro was evaluated following adoptive transfer in intestinal tissues or the central nervous system (CNS). Key findings were validated in an αCD3-stimulated humanised NSG mouse model reconstituted with peripheral blood mononuclear cells from patients with PSC. RESULTS: NorUDCA suppressed TH17 effector function and enriched regulatory T cell (Treg) abundance upon CD4+TNaive cell transfer. NorUDCA mitigated intraepithelial TH17 pathogenicity and decreased the generation of proinflammatory 'TH1-like-TH17' cells, and enhanced TH17 transdifferentiation into Treg and Tr1 (regulatory type 1) cells in the αCD3-model. In vivo ablation revealed that Treg induction is crucial for NorUDCA's anti-inflammatory effect on TH17 pathogenicity. Mechanistically, NorUDCA restrained pTH17 effector function and simultaneously promoted functional Treg formation in vitro, by attenuating a glutamine-mTORC1-glycolysis signalling axis. Exposure of pTH17 to NorUDCA dampened their pathogenicity and expansion in the intestine or CNS upon transfer. NorUDCA's impact on TH17 inflammation was corroborated in the humanised NSG mouse model. CONCLUSION: NorUDCA restricts TH17 inflammation in multiple mouse models, potentiating future clinical applications for treating TH17-mediated intestinal diseases and beyond.
引用
- Zhu C, Boucheron N, Al-Rubaye O, et al. 24-Nor-ursodeoxycholic acid improves intestinal inflammation by targeting TH17 pathogenicity and transdifferentiation. Gut. 2025. PMID: 40032499. doi:10.1136/gutjnl-2024-333297
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。